7:27 AM ET
8-K
Clinical Trial Data
Invivyd Clinical Trial Data
Invivyd announced positive topline results from its LIBERTY Phase 3 study, which demonstrated that its COVID-19 monoclonal antibody candidate, VYD2311, had safety and tolerability superior to an mRNA-based vaccine. The company plans to use data from LIBERTY and the ongoing DECLARATION pivotal study to support a Biologics License Application (BLA) submission to the FDA via the Accelerated Approval Program.
- Earnings call
- Sep 29, 2026, 8:30 AM ET